Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus SELENOMETHIONINE SE 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus SELENOMETHIONINE SE 75.
CERETEC vs SELENOMETHIONINE SE 75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
Radiopharmaceutical agent: selenium-75 decays by electron capture to arsenic-75 with emission of gamma photons. Used as a tracer for pancreatic imaging due to incorporation into pancreatic enzymes. Localizes in pancreas via protein synthesis.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
0.185-0.37 MBq (5-10 μCi) intravenously as a single dose for pancreatic imaging.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
Terminal half-life is approximately 50-60 days, reflecting slow turnover of selenomethionine incorporated into body proteins (e.g., skeletal muscle, erythrocytes).
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Primarily renal, with 20-30% excreted unchanged in urine; minor fecal elimination (<5%). The remainder is incorporated into endogenous proteins and long-term tissue stores.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical